Mirum Pharmaceuticals Inc

CEO insider trading at Mirum Pharmaceuticals shows strategic buying, tax‑related selling, and long‑term stake—an insight for investors.

Insider buying by Mirum’s senior controller signals confidence amid volatility; discover how this move contrasts with CEO sales and what it means for investors.

Mirum’s top execs just grabbed massive stock options & RSUs— a bold sign of confidence amid rising share price and negative earnings. See what this insider surge could mean for investors.

Radovich Peter’s recent buy of 5,750 Mirum shares signals executive confidence amid a strong earnings beat, 104% yearly rally, and pipeline optimism, offering investors a bullish hint to watch.

Insider buy at Mirum Pharmaceuticals signals confidence amid a 104 % rally; 159k shares purchased by owner Heron Patrick J at $99.27, boosting optimism for liver‑disease pipeline.

Mirum insider Saira Saira’s buy‑sell‑option trades reveal a risk‑managed strategy that signals confidence in Mirum’s growth, while her pattern of buying low and selling high underscores a bullish outlook on the company’s prospects.